Chimeric Antigen receptor-T (CAR-T) cells targeting Epithelial cell adhesion molecule (EpCAM) can inhibit tumor growth in ovarian cancer mouse model

• Published in: Journal of Veterinary Medical Science Vol. 83; no. 2; pp. 241 - 247
• Main Authors: FU, Juan, SHANG, Yuhong, QIAN, Zhang, HOU, Jinping, YAN, Feng, LIU, Guodi, DEHUA, Li, TIAN, Xiaoli
• Format: Journal Article
• Language: English
• Published: Japan JAPANESE SOCIETY OF VETERINARY SCIENCE 2021; The Japanese Society of Veterinary Science
• Subjects: Animals; Cell Line, Tumor; chimeric antigen receptor T cells; Epithelial Cell Adhesion Molecule; Female; immunodeficient mice; Immunology; immunotherapy; Immunotherapy, Adoptive - veterinary; Mice; ovarian cancer; Ovarian Neoplasms - therapy; Ovarian Neoplasms - veterinary; Receptors, Antigen, T-Cell; Receptors, Chimeric Antigen; Xenograft Model Antitumor Assays - veterinary; immunodeficient mice; chimeric antigen receptor T cells; ovarian cancer; immunotherapy; epithelial cell adhesion molecule

Ovarian cancer (OC) is one of the most lethal solid tumors with poor prognosis. In 2017, two chimeric antigen receptor-T (CAR-T) cell drugs were approved by the U.S. Food and Drug Administration (FDA), and continuously optimized CAR-T cells therapy might be the novel hope for OC patient. EpCAM are k...